title: Prevention of adjuvant arthritis by cyclosporine in rats.
abstract: The effect of cyclosporine A during the development phase of adjuvant arthritis was studied in 40 female rats. Five groups of eight animals each received oral cyclosporine, 2.5, 5, 10, 20, or 30 mg/kg daily for 30 days. Also, eight normal and eight diseased rats served as placebo controls. At the time of inoculation of the adjuvant suspension on day 0, measurement of disease parameters (paw swelling and vertebral density) was started concomitantly with beginning of therapy. On completion of the study, the animals were killed, and after measurement of total skeletal and segmental (hind legs and caudal spine plus two caudal vertebrae) calcium, the two assessed vertebrae and both femoral condyles were removed for histomorphometric evaluation (vertebrae) and for estimation of glycosaminoglycan (GAG) content of cartilage. Blood for osteocalcin determinations also was taken at term from control and untreated arthritic rats and from animals that had received 10 mg/kg cyclosporine. Treatment with 2.5 mg/kg was ineffective, but doses between 5 and 20 mg/kg prevented the development of articular and osseous lesions. The 20 mg/kg dose showed no better effect than 10 mg/kg. This was shown by the absence of inflammation and the presence of normal condylar GAG and total mineral content in the areas screened. Untreated animals showed marked reductions in all of these parameters. The 30 mg/kg dose was effective in blocking the GAG loss, but significant reductions in bone density and trabecular volume were seen. There was a close correlation between GAG and bone density values, suggesting a common causal relationship. Circulating osteocalcin was significantly elevated in the untreated animals with adjuvant arthritis.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Sandoz Research Institute Berne Ltd, Switzerland.
authors.forename: E
authors.initials: E
authors.lastname: del Pozo
authors.forename: P
authors.initials: P
authors.lastname: Elford
authors.forename: R
authors.initials: R
authors.lastname: Perrelet
authors.forename: M
authors.initials: M
authors.lastname: Graeber
authors.forename: J P
authors.initials: JP
authors.lastname: Casez
authors.forename: D
authors.initials: D
authors.lastname: Modrowski
authors.forename: T
authors.initials: T
authors.lastname: Payne
authors.forename: A R
authors.initials: AR
authors.lastname: MacKenzie
mesh_terms: D000818:Animals; D001169:Arthritis, Experimental / Q000517:prevention & control*; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism; D002118:Calcium / Q000378:metabolism; D002356:Cartilage / Q000737:chemistry; D016572:Cyclosporine / Q000494:pharmacology*; D004487:Edema / Q000517:prevention & control; D005260:Female; D005528:Foot; D015675:Osteocalcin / Q000097:blood; D051381:Rats; D013131:Spine / Q000378:metabolism / Q000473:pathology
chemical_list: D015675:Osteocalcin; D016572:Cyclosporine; D002118:Calcium